Ryan Allway March 3rd, 2021 Psychedelics Novamind Inc., (CSE:NM)(OTC PINK:NVMDF) (“Novamind”), a leading mental health company specialized in psychedelic medicine, announces the appointment of Joseph Braganza to the role of Senior Vice President, Head of M&A. Mr. Braganza joins the senior leadership team with a mandate to lead Novamind’s... Read more

Ryan Allway March 1st, 2021 Psychedelics Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine”), an emerging biopharma company in the life sciences category committed to the research and development, production, and acceptance of alternative nature-sourced medicine for mainstream use, has completed the world’s first international legal export... Read more

Ryan Allway March 1st, 2021 Psychedelics Novamind Inc. (CSE:NM)(OTC PINK:NVMDF) (“Novamind”), a leading mental health company specialized in psychedelic medicine, today reported its fiscal second quarter results for the three months ended December 31, 2020 (“Fiscal Q2 2021″). The Company’s fiscal year-end is June 30th. All results are reported... Read more

Ryan Allway March 1st, 2021 Psychedelics Newscope Capital Corporation (“Newscope”) (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce today that its common shares are now eligible... Read more

Ryan Allway March 1st, 2021 Psychedelics Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3)  (“Core One”) a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market, is pleased to announce readiness to begin initial biosynthetic psilocybin production trials. The Company’s... Read more

Ryan Allway February 25th, 2021 Psychedelics PsyBio Therapeutics Corp. (formerly Leo Acquisitions Corp.) (TSXV: PSYB) is pleased to announce that at the opening of the market today, the Company’s subordinate voting shares will commence trading on the TSX Venture Exchange (the “TSXV”) under the ticker symbol “PSYB”. On February... Read more

Ryan Allway February 25th, 2021 Psychedelics Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC: TRUFF) (“Red Light Holland“, an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, is extremely pleased to announce... Read more

Ryan Allway February 25th, 2021 Psychedelics Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF)(“NOVA”), a leader in the development of psilocybin and other psychedelic compounds with broad cognitive, behavioral, and peripheral physiologic effects, has received approval for its first clinical program in Autism Spectrum Disorder (ASD).... Read more

Ryan Allway February 25th, 2021 Psychedelics YUKOTERRE RESOURCES INC. (“Yukoterre”) (CSE:YT), is pleased to announce that further to the press release dated August 25, 2020, it has obtained conditional approval from the Canadian Securities Exchange (the “CSE”) for the listing of the common shares (the “Resulting Issuer Shares”) that... Read more

Ryan Allway February 25th, 2021 Psychedelics Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (“Entheon“), a biotechnology company focused on developing psychedelic medicines to treat addiction, provides a production update on HaluGen Life Sciences Inc. (“HaluGen“), a wholly-owned subsidiary of Entheon, which is in the business of developing and commercializing... Read more